Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: Molecular and behavioral aspects

[1]  Horst Kessler,et al.  Improvement of drug-like properties of peptides: the somatostatin paradigm , 2010, Expert opinion on drug discovery.

[2]  H. Manji,et al.  Novel Insights into Lithium’s Mechanism of Action: Neurotrophic and Neuroprotective Effects , 2010, Neuropsychobiology.

[3]  C. Gilon,et al.  The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. , 2010, Bioorganic & medicinal chemistry.

[4]  T. Steckler,et al.  IMPA1 is Essential for Embryonic Development and Lithium-Like Pilocarpine Sensitivity , 2008, Neuropsychopharmacology.

[5]  Zhimin Xiang,et al.  Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. , 2008, Journal of medicinal chemistry.

[6]  T. Gould,et al.  Animal models of bipolar disorder and mood stabilizer efficacy: A critical need for improvement , 2007, Neuroscience & Biobehavioral Reviews.

[7]  R. Belmaker,et al.  Lithium–pilocarpine seizures as a model for lithium action in mania , 2007, Neuroscience & Biobehavioral Reviews.

[8]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[9]  C. Gilon,et al.  Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. , 2007, Journal of medicinal chemistry.

[10]  Sudhir C. Sharma,et al.  Design, synthesis, and evaluation of linear and cyclic peptide ligands for PDZ10 of the multi-PDZ domain protein MUPP1. , 2007, Biochemistry.

[11]  R. Belmaker,et al.  Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss , 2007, Behavioural pharmacology.

[12]  Jungkyun Im,et al.  Spatial Expression Patterns and Biochemical Properties Distinguish a Second myo-Inositol Monophosphatase IMPA2 from IMPA1* , 2007, Journal of Biological Chemistry.

[13]  D. Clapham,et al.  Calbindin‐D28K dynamically controls TRPV5‐mediated Ca2+ transport , 2006, The EMBO journal.

[14]  R. Kumar,et al.  Structure, binding interface and hydrophobic transitions of Ca2+-loaded calbindin-D28K , 2006, Nature Structural &Molecular Biology.

[15]  J. Eilers,et al.  Calbindin D28k targets myo-inositol monophosphatase in spines and dendrites of cerebellar Purkinje neurons. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Belmaker,et al.  Interaction of calbindin D28k and inositol monophosphatase in human postmortem cortex: possible implications for bipolar disorder. , 2005, Bipolar disorders.

[17]  J. Woodgett,et al.  Glycogen Synthase Kinase-3β Haploinsufficiency Mimics the Behavioral and Molecular Effects of Lithium , 2004, The Journal of Neuroscience.

[18]  A. Harwood,et al.  Search for a common mechanism of mood stabilizers. , 2003, Biochemical pharmacology.

[19]  A. Konnerth,et al.  Calbindin in Cerebellar Purkinje Cells Is a Critical Determinant of the Precision of Motor Coordination , 2003, The Journal of Neuroscience.

[20]  Maria Blatow,et al.  Ca2+ Buffer Saturation Underlies Paired Pulse Facilitation in Calbindin-D28k-Containing Terminals , 2003, Neuron.

[21]  S. Linse,et al.  myo-Inositol Monophosphatase Is an Activated Target of Calbindin D28k* , 2002, The Journal of Biological Chemistry.

[22]  C. Beasley,et al.  Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins , 2002, Biological Psychiatry.

[23]  A. Harwood,et al.  A common mechanism of action for three mood-stabilizing drugs , 2002, Nature.

[24]  J. Enghild,et al.  Calbindin D28k Exhibits Properties Characteristic of a Ca2+ Sensor* , 2002, The Journal of Biological Chemistry.

[25]  C. Beasley,et al.  The density and spatial distribution of gabaergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia , 2002, Biological Psychiatry.

[26]  G. Elston,et al.  The human temporal cortex: characterization of neurons expressing nitric oxide synthase, neuropeptides and calcium-binding proteins, and their glutamate receptor subunit profiles. , 2001, Cerebral cortex.

[27]  W. Strittmatter,et al.  Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. , 2001, Biochemical and biophysical research communications.

[28]  P. Emson,et al.  Relationship of calbindin D28K‐immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.

[29]  R. Ebstein,et al.  Inositol Monophosphatase Activity in Brain and Lymphocyte-Derived Ceii Lines of Bipolar Patients , 2001, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[30]  T. Schermerhorn,et al.  Calbindin-D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and beta cell lines. , 1999, The Journal of biological chemistry.

[31]  D. Oren,et al.  Miniaturized proteins: the backbone cyclic proteinomimetic approach. , 1999, Journal of molecular biology.

[32]  J. Crawley.  Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests 1 Published on the World Wide Web on 2 December 1998. 1 , 1999, Brain Research.

[33]  S. Linse,et al.  Expression and purification of human calbindin D28k. , 1999, Protein expression and purification.

[34]  J. Hoflack,et al.  Inhibition of myo-inositol monophosphatase isoforms by aromatic phosphonates. , 1998, Bioorganic & medicinal chemistry.

[35]  H. Soininen,et al.  Distribution of parvalbumin‐, calretinin‐, and calbindin‐D28k–immunoreactive neurons and fibers in the human entorhinal cortex , 1997, The Journal of comparative neurology.

[36]  J. Atack.  Inositol monophosphatase inhibitors—Lithium mimetics? , 1997, Medicinal research reviews.

[37]  O. Garaschuk,et al.  Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Borchardt,et al.  Effect of Restricted Conformational Flexibility on the Permeation of Model Hexapeptides Across Caco-2 Cell Monolayers , 1997, Pharmaceutical Research.

[39]  D. Melton,et al.  A molecular mechanism for the effect of lithium on development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Pollack,et al.  Inositol monophosphatase — a putative target for Li+ in the treatment of bipolar disorder , 1995, Trends in Neurosciences.

[41]  S. Pollack,et al.  Structure and mechanism of inositol monophosphatase , 1995, FEBS letters.

[42]  R. Belmaker,et al.  Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression , 1993, Biological Psychiatry.

[43]  D Gani,et al.  Chemical and kinetic mechanism of the inositol monophosphatase reaction and its inhibition by Li+. , 1993, European journal of biochemistry.

[44]  E. Katchalski‐Katzir,et al.  Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Byk,et al.  Backbone cyclization: A new method for conferring conformational constraint on peptides , 1991, Biopolymers.

[46]  M. Mattson,et al.  Evidence for calcium-reducing and excitoprotective roles for the calcium-binding protein calbindin-1328k in cultured hippocampal neurons , 1991, Neuron.

[47]  M. Celio,et al.  Calbindin D-28k and parvalbumin in the rat nervous system , 1990, Neuroscience.

[48]  M. Berridge.  Inositol Trisphosphate, Calcium, Lithium, and Cell Signaling , 1989 .

[49]  M. Berridge,et al.  Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. , 1982, The Biochemical journal.

[50]  Richard T. Linn,et al.  Responses to cortical injury: I. Methodology and local effects of contusions in the rat , 1981, Brain Research.

[51]  W. Sherman,et al.  The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. , 1980, The Journal of biological chemistry.

[52]  M. Reilly,et al.  Protein–protein interactions as therapeutic targets in neuropsychopharmacology , 2009, Neuropsychopharmacology.

[53]  R. Borchardt,et al.  Esterase-Sensitive Cyclic Prodrugs of Peptides: Evaluation of a Phenylpropionic Acid Promoiety in a Model Hexapeptide , 2004, Pharmaceutical Research.

[54]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[55]  Peter Gwynne,et al.  Drug Discovery: 5 , 2002 .

[56]  S. Freeman,et al.  Inhibitors of inositol monophosphatase. , 1999, Journal of enzyme inhibition.

[57]  Leighton Coates,et al.  Biological Crystallography High-resolution Structure of Myo-inositol Monophosphatase, the Putative Target of Lithium Therapy , 2022 .